Month: September 2021

Item 9 Labs (INLB) – Expanding Unity Rd. Footprint

Posted on by Admin

Tuesday, September 28, 2021

Item 9 Labs (INLB)
Expanding Unity Rd. Footprint

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Agreements. Item 9 Labs announced continued development of its cannabis dispensary franchise brand, Unity Rd., across the Northeastern United States with new signed agreements for development in New Jersey and Virginia and the signing of a lease for the first Unity Rd. dispensary in Maine by an existing partner. Unity Rd. has multiple agreements signed with more than 15 entrepreneurial groups who are in various stages of development across eight states.

    New Jersey.  Adult use was approved by voters in November 2020 and in August regulators approved initial rules for the program that will set up the state’s retail market. The New Jersey market is projected to hit around $750 million of sales in the first full year growing to $2.1 billion in the fourth year …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

Posted on by Admin


Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

 

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

AUSTIN, Texas — (September 28, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.  Drs. Berger and Kumar will report to  Rodney Varner, Chief Executive Officer of Genprex. 

“It is my priviledge and pleasure to welcome Mark and Hemant to our management team.  Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner.  “As we continue to make progress with these studies, and to expand our technology pipeline, it is more important than ever to have medical affairs and manufacturing in such capable hands.”

“I am delighted to join the growing team at Genprex, confident that my experience designing and managing pivotal clinical trials in oncology will provide valuable insight and oversight for Genprex’ novel gene therapy pipeline,” commented Dr. Berger. “Advancing the first systemic gene therapy in oncology is  a uniquely exciting opportunity to transform cancer care for patients with limited treatment options and I am looking forward to working with Genprex’ leadership team to help develop this new approach to cancer treatment.”  

“I am delighted to join the management team at Genprex and to work alongside this group of seasoned executives to realize the potential for its novel systemic gene therapy to improve outcomes for cancer patients,” noted Dr. Kumar.  “I am eager to apply my expertise and technical background in accelerated development of innovative biologics and advanced cell and gene therapies to support Genprex’ already impressive work and drive its technologies to commercialization.” 

About Mark S. Berger

Dr. Berger is an oncologist and senior executive with 25 years of biotech and pharmaceutical company experience in the development of oncology therapeutics.  He has successfully brought two drugs through the regulatory process to approval and excels in strategic development, team management and collaborative leadership. Dr. Berger joins Genprex from Actinium Pharmaceuticals, Inc. where since January 2017 he served as Chief Medical Officer and was responsible for clinical strategy and development of radioisotope-labeled antibodies for therapy in oncology, including the Company’s Phase 3 SIERRA trial.  Before that, Dr. Berger was Senior Vice President-Clinical Research at Kadmon Corporation from 2013 through 2017, where he led all aspects of the company’s new drug development, including clinical trial design and management of the oncology programs in non-small cell lung cancer and breast cancer, among others. 

Prior to that, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013. Before Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent. He presented the Mylotarg clinical data at the FDA’s Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML.

Dr. Berger holds a B.A. in biology from Wesleyan University and a M.D. from the University of Virginia School of Medicine. He did his Hematology/Oncology fellowship at the University of Pennsylvania, where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology. 

About Hemant Kumar, Ph.D., CPM, EMBA

Dr. Kumar is a recognized global expert in Chemistry, Manufacture and Controls (CMC) Technical Development and GMP manufacturing.  He has a greater than 25-year track record leading global CMC and regulatory approval strategy for accelerated development of innovative vaccines, biologics, advanced cell & gene therapy drug process and product development (Ph1 to Ph3 and commercialization) under current GMP, and licensing processes. Dr. Kumar joins Genprex from Arcturus Therapeutics, Inc., where he served as Strategic Advisor and then Vice President, Global Head of Manufacturing, Supply Chain, and Strategy.  Prior to that, Dr. Kumar was Vice President of CMC Technical Development & Manufacturing Operations at Oncoimmune Therapeutics, Inc., a private company that was acquired by Merck & Co. during his tenure there.  Before that, he was Vice President, Head of Global Process Sciences and Clinical Manufacturing Operations at Rentscher BioPharma, SE.  Previous to that, Dr. Kumar was with Anaptysbio, Inc., where he served as Senior Vice President, Head of Global CMC, Technical Development and Manufacturing Operations.   Before that, Dr. Kumar held senior level positions of increasing manufacturing and technical operations leadership in global biopharmaceutical companies including Merck & Co., Inc.,  Sanofi Genzyme, Inc., Lonza Biologics, Inc., Sanofi Pasteur, Janssen Biotech ( a Johnson & Johnson company) and Wyeth Lederle Vaccines, Inc.

Dr. Kumar earned his Ph.D. in Biochemistry at J.N. Medical College, Aligarth India through a collaboration with the U.S. National Institutes of Health. He holds a graduate certificate in Project Management from Lehigh University School of Management.  Dr. Kumar has conducted postdoctoral and research scientist fellowships at Yale University School of Medicine, the University of Rhode Island and the Center for Disease Control and Prevention’s Center for Infectious Diseases.  He holds professional affilations with the American Chemical Society, American Association for the Advancement of Science, Americal Society for Microbiology and the International Society of Pharmaceutical Engineers.  

Inducement Grants

The Company has granted 550,000 options to Dr. Berger at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under Genprex’s 2018 Equity Incentive Plan (the “Plan”), the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

The Company has granted 400,000 options to Dr. Kumar at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under the Plan, the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

investors@genprex.com

Media Contact

Genprex Media Relations

Anne Marie Fields

(877) 774-GNPX (4679) ext. #3

afields@rxir.com

Kratos Receives $3.2 Million Contract Award for Next Generation Small Engine Development for National Security Program

Posted on by Admin


Kratos Receives $3.2 Million Contract Award for Next Generation Small Engine Development for National Security Program

 

SAN DIEGO, 
Sept. 28, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that its Kratos Turbine Technologies (KTT) Business has recently received an approximate 
$3.2 million contract award for the development of a Next Generation small engine for a National Security Program.  KTT is currently under contract and in development for several Next Generation turbojet, turbofan, and other engines for certain National Security priority areas, including unmanned aerial drone systems, cruise missiles, powered munitions and other platforms and systems.  Work under this recent contract award will be performed at a secure Kratos technical, engineering and development facility.  Due to customer, competitive and other considerations, no additional information is being provided related to this recent contract award.

Stacey Rock, President of KTT, said, “At Kratos, affordability is a technology, and KTT is focused on disrupting the small turbojet and turbofan class market area with a family of new, high performance, high power, affordable engines which address our customers’ rapidly expanding requirements.  We believe that Kratos’ digital engineering capabilities, which utilize an integrated digital approach with authoritative sources of system data and models across our entire organization’s functions and disciplines is a competitive differentiator for our Company and significant value contributor for our customers.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Release – Orion Group Holdings Inc Announces Contract Awards of Approximately $22 Million Value Could Increase

Posted on by Admin

 


Orion Group Holdings, Inc. Announces Contract Awards of Approximately $22 Million; Value Could Increase

 

HOUSTON–(BUSINESS WIRE)–Sep. 28, 2021– 
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced three contract awards totaling approximately 
$22 million.

The Company’s Marine segment has been awarded three contracts valued at a combined 
$22 million to perform dredging services for the 
US Army Corps of Engineers (USACE) in waterways along the gulf coast, with the potential for the contract value on one award to increase by up to 
$19 million.

Two of these contracts were recently awarded by the USACE’s 
Galveston District for dredging work on the 
Texas coast. The first award valued at 
$8.8 million calls for the removal of up to two million cubic yards of maintenance material along the 
Gulf Intracoastal Waterway between 
Corpus Christi and 
Port Isabel. The second award, located in the 
Sabine Neches Waterway in 
Jefferson County, Texas, is valued at a base amount of 
$9.5 million for the dredging of 2.1 million cubic yards of material. If the USACE exercises all options for additional scope of work, the total value for this contract could grow to over 
$28 million.

The third award is a 
$3.5 million contract from the USACE’s 
Jacksonville District to dredge maintenance material from the upper channels in 
Tampa Harbor, in 
Tampa, Florida. Work on all three projects is expected to commence during the fourth quarter of 2021, with completion expected late next year.

“Maintaining our nation’s waterways is critical to the economy of our country and being able to continue to support the 
US Army Corps of Engineers in executing their mission is equally critical to Orion,” said  Mark Stauffer, Orion’s President and Chief Executive Officer. “We have several ongoing projects for the 
US Army Corps of Engineers and the addition of these projects adds to the growing backlog in our marine business.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental 
United States, 
Alaska, 
Canada and the 
Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in 
Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on 
March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.
Francis Okoniewski, Vice President Investor Relations
(346) 616-4138
fokoniewski@orn.net
www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO
(713) 852-6500
www.oriongroupholdingsinc.com

Source: 
Orion Group Holdings, Inc.

Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600%

Posted on by Admin


Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600%

 

also receives amended drilling permit for follow-up drilling at RECENT high-grade discovery AT EASTSIDE

Reno, Nevada /September 28, 2021 – Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is very pleased to announce the receipt of two permits allowing for a significant expansion of drilling and operations at its Flagship Eastside Project (Inferred ounces of 1.4M Au and 8.7M Ag*) near the town of Tonopah, Nevada. The first permit expands the Plan-of-Operations (“PoO”) from the previous 600 acres to over 3,676 acres around the Original Pit Zone. The second permit received amends the existing drill target plan within the Original Pit Zone and will allow Allegiant to drill up to 14 new diamond core holes to test the recently discovered high-grade zone announced on May 26, 2021. Highlights of that announcement included:

  • Strong gold intercepts in Holes 239, 243, 244 and 245
  • Mineralization encountered in 7 of 9 holes
  • Significant silver in Holes 243 and 239
  • Hole 243 included 2.55 g/t Au over 147.8 metres (3.17 g/t Au over 117.3m)
  • Hole 239 included 111.3m of 1.45 g/t Au including 3.1 metres of 39 g/t at the bottom of the hole.
  • Hole 244 included 76 metres of mineralization with best intercept being 6.1m of 1.48 g/t Au
  • Hole 245 included 15.2 metres of 3.4 g/t Au from relatively shallow depths (177m)
  • Eastside remains open in all directions and at depth in both the Original Pit Zone and the Castle Zone

Peter Gianulis, CEO of Allegiant Gold, commented: “The receipt of the two permits is a major development that will allow us to further expand beyond the existing Original Pit Zone at Eastside as well as offset drilling around the recently discovered high-grade zone. We embarked on this expanded Plan-of-Operations over 18 months ago with the plan of testing geochemical and geophysical anomalies that have never been previously drilled. We look forward to executing our business plan which includes significant drilling.”

The newly approved PoO allows Allegiant to build new roads and access to 160 new drill sites to test gold, arsenic, and intense hydrothermal alteration zones continuing south and west of the existing resource for at least 2-3 km. It also allows Allegiant to drill geophysical anomalies on the pediment east of our existing resource which are interpreted to be rhyolite domes known to be key for hosting gold at Eastside. Allegiant plans to provide a comprehensive update on the business plan and the upcoming drilling in the near future.

*The updated resource estimate (“Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project Technical Report, Esmeralda County, Nevada”) was conducted by Mine Development Associates (“MDA”), a division of RESPEC of Reno, Nevada with an effective date of July 30, 2021. Contained pit-constrained Inferred Resources (cut-off grade of 0.15 g/t) of 1,090,000 Au ounces in 61,730,000 tonnes at 0.55 g/t Au and 8,700,000 Ag ounces at 4.4 g/t Ag at the Original Pit Zone and 314,000 Au ounces in 19,986,000 tonnes at 0.49 g/t Au at the Castle Area. In accordance with NI 43-101, the MDA Technical Report dated July 30, 2021, will be filed on SEDAR. This report builds on and supersedes the NI 43-101 reports of Ristorcelli (December 2016), Ristorcelli (July 2017) and Ristorcelli (January 2020) titled “Amended Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project, Esmeralda County, Nevada” prepared for Allegiant with an Effective Date of December 30, 2019.

See Eastside expanded permit area here:

Map 1: Expanded Permit Area Map
https://allegiantgold.com/site/assets/files/2209/eastside-expanded-permit-area-map.jpg

QUALIFIED PERSON

Andy Wallace is a Certified Professional Geologist (CPG) with the American Institute of Professional Geologists and is the Qualified Person under NI 43-101, Standards of Disclosure for Mineral Projects, who has reviewed and approved the scientific and technical content of this press release.

ABOUT ALLEGIANT

Allegiant owns 100% of 10 highly-prospective gold projects in the United States, 7 of which are located in the mining-friendly jurisdiction of Nevada. Four of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

ON BEHALF OF THE BOARD

Peter Gianulis
CEO

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364
ir@allegiantgold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of applicable U.S. securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws, which are referred to collectively as “forward-looking statements”. The United States Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements.Allegiant Gold Ltd.’s (“Allegiant”) exploration plans for its gold exploration properties, the drill program at Allegiant’s Eastside project, the preparation and publication of an updated resource estimate in respect of the Original Zone at the Eastside project, Allegiant’s future exploration and development plans, including anticipated costs and timing thereof; Allegiant’s plans for growth through exploration activities, acquisitions or otherwise; and expectations regarding future maintenance and capital expenditures, and working capital requirements. Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. Such forward-looking statements are based on a number of material factors and assumptions and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on forward-looking statements contained in this press release. Some of the known risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements are described in the sections entitled “Risk Factors” in Allegiant’s Listing Application, dated January 24, 2018, as filed with the TSX Venture Exchange and available on SEDAR under Allegiant’s profile at www.sedar.com. Actual results and future events could differ materially from those anticipated in such statements. Allegiant undertakes no obligation to update or revise any forward-looking statements included in this press release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Source: Allegiant Gold Ltd.

Will SPACs Get Recharged on Polestar EV Merger?

Posted on by Admin

Will SPACs Get Recharged on Polestar EV Merger?

 

Investment success always attracts increased interest to the investment type. It isn’t unusual for the type to then begin to attract more interest than practical given a finite world. If there is over-speculation, investors may then pull back their interest – over time the market and investors find a smart balance. At times the regulators interject their own leverage as well.

Last Year’s SPAC successes created a surge of new blank check SPAC IPOs into the first quarter of 2021. They were all seeking that “one-of-a-kind” must own target. Investors were at first caught up in the buzz, then the so-called blank check companies had digestion problems.  Electric car companies may have also become bloated around that time. It seemed that every week we learned of another EV start-up somewhere in the world. These companies are all vying to be the next great car company in a greener world. It isn’t likely the world is big enough for all of them to amass that kind of success.

 

20 Billion Reasons to Still Pay Attention to SPACs

SPAC managers Gores Guggenheim, Inc. may have demonstrated that there are still incredible companies to be found and merge with. Yesterday, shareholders of one of their SPACs woke up to learn they will have the option of owning a pro-rata share of a 6% stake in a car company that post-merger will be worth $20 billion. The proposed business combination was unanimously approved by both the Board of Directors of Gores Guggenheim and the Board of Directors of Polestar. It’s expected to close in the first half of 2022, subject to approval by Gores Guggenheim’s stockholders and other standard closing conditions.

 

Summarizing the Deal

The Nasdaq listed SPAC managed by Gores will be acquiring a portion of Polestar which is owned by Volvo Car Group and the chairman of Zhejiang Geely Holding Group Co. Actor Leonardo DiCaprio will also own a stake in the final deal (Volvo is currently a subsidiary of Geely). A combination with Gores Guggenheim Inc. first attempted in July, has now been set in motion. The SPAC’s shareholders, managers, and new external investors together will own an initial 6% stake, their contribution is $1.1 billion of cash. This is how the Gores website defined the transaction.

 

  • Polestar is a global pure-play, premium electric vehicle (“EV”) company based in Sweden, with a mission to produce progressive, electric performance cars designed and engineered without compromise
  • The transaction implies an enterprise value of approximately USD 20 billion
  • Polestar currently has two award-winning cars in production and rapidly growing sales in 14 active markets across three continents
  • Proceeds from the business combination are expected to be used to help fund significant investment in products and the expansion of operations and markets to create a leading company in the rapidly growing global premium EV market
  • The transaction includes approximately USD 800 million of cash from Gores Guggenheim, Inc.’s trust account (subject to applicable stockholder redemption rights) and USD 250 million in cash from PIPE financing anchored by top-tier institutional investors
  • Existing Polestar investors include Volvo Car Group and affiliates of Geely Chairman Eric Li, and actor and activist Leonardo DiCaprio, amongst others
  • Polestar EVs are expected to be built in the Volvo South Carolina plant

 

Other SPAC News

SEC Chair Gensler spoke today (September 28) and worried aloud about the lack of definition, in some cases, around what SPACs can do with investors’ money. He noted how the structure incentivizes SPACs to find a merger deal “even if it’s not a particularly great merger”—potentially at the expense of the investors they are raising money from. The SEC has also recommended changes to accounting rules related to how SPAC investors are viewed relative to others involved.

 

Take-Away

The Polestar + Gores Guggenheim SPAC + Volvo + Leonardo DiCaprio business combination appears to have the potential to launch an EV manufacturer upward financially where they have the resources to design, build, and compete at a high level. This seems as though it meets or exceeds the objectives of all involved in this SPAC IPO through the expected merger.  The car company has the resources to grow much faster, and the investors are involved in a situation they may not have been offered otherwise.

Investors have been shying away from SPACs. Perhaps this will become the success that causes those that retrenched to regain interest and the SPAC market will attain a sustainable balance.

 

Suggested Reading:



Irrational Pessimism – Why Value Investors Should Research Individual SPACs

One Great Protection Inherent in SPACs for Investors





Regulation of a Special Purpose Acquisition Company

Analysis of a Special Purpose Acquisition Company

 

Sources:

https://www.gores.com/wp-content/uploads/2021/09/Press-Release-Polestar-Signs-Agreement-to-be-Publicly-Listed-Through-Combination-with-Gores-Guggenheim-Inc.pdf

https://www.bloomberg.com/news/articles/2021-09-13/china-has-too-many-electric-carmakers-m-a-to-be-encouraged

https://www.polestar.com/us/

https://www.barrons.com/articles/electric-vehicle-maker-polestar-in-talks-20-billion-spac-deal-51632735270?refsec=news

 

Stay up to date. Follow us:

 

Release – Neovasc REDUCER-I Study Published in EuroIntervention Journal

Posted on by Admin


Neovasc REDUCER-I Study Published in EuroIntervention Journal

 

VANCOUVER and MINNEAPOLIS – (NewMediaWire) – September 28, 2021 – Neovasc, Inc. (Neovasc or the Company) (NASDAQ TSX:NVCN) today announced the publication of an article entitled, Coronary sinus narrowing for the treatment of refractory angina: a multi-centre prospective open-label clinical study (the REDUCER-I study) in the September 2021 issue of the journal EuroIntervention.

The articles lead authors areStefan Verheye, MD, PhD, Cardiovascular Center, ZNA Middelheim Hospital, Antwerp, Belgium, and Maayan Konigstein, MD, from the Tel Aviv Medical Center, Tel Aviv, Israel. The publication provides interim results from the REDUCER-I study investigating patients suffering from refractory angina treated with the Neovasc Reducer(TM) (Reducer) system.The REDUCER-I study is a prospective, open-label, multi-center, international, post-market study, (with a retrospective component) which collects long-term data of patients with refractory angina treated with the Reducer. The publication outlines the overall clinical outcomes of the first 228 patients enrolled.

The primary efficacy endpoint was the percentage of patients who experience improvement in their angina symptoms defined as a reduction in Canadian Cardiovascular Society (CCS) grade, a measure of their disability, at six months as compared to baseline. The primary safety endpoints are the rate of occurrence of device- and/or procedure-related periprocedural serious adverse events, and major adverse cardiac events (MACE), a composite of cardiac death, major stroke and myocardial infarction up to 30 days post implant.

In the first 228 patients (81% male, 68.39.6 years), the procedural success rate was very high (99%), with a very high safety profile that translated to only one adjudicated possible procedural or device-related MACE. Mean CCS class improved from 2.80.6 at baseline, to 1.80.7 at two years. Improvement in 1 CCS class was observed in 82%, and in 2 CCS classes in 31% of patients at two years. At baseline, 70% of the cohort were disabled at very minimal physical effort (reported to be in CCS class III-IV); this portion was reduced to only 15% at follow-up. Additional measured parameters of functional class and quality of life were also improved.

The data published in the REDUCER-I study confirm the high safety profile of the therapy in patients suffering from refractory angina. The results also demonstrate sustained improvement in angina severity and in quality of life up to two years, said Prof. Verheye. I am encouraged that we now have a therapy to offer patients whom, in the past, had no treatment options. In properly selected patients, the Reducer offers hope for a return to a more normal life that is less hampered by the debilitating symptoms of refractory angina.

An accompanying editorial, Coronary sinus reducer therapy for refractory angina: is it ready for prime time? was published in the same issue of EuroIntervention. Authored by Dr. Michael Foley, MBBS, BSc and Dr. Rasha Al-Lamee, MBBS, MA, PhD, both from National Heart and Lung Institute, Imperial College London, United Kingdom, the editorial states, The most important additive finding of REDUCER-I is the real-world procedural success and safety of a new device. The authors further suggest that the ongoing ORBITA-COSMIC study and the upcoming COSIRA-II trial will be helpful to validate the Reducer device for an important and often overlooked clinical group.

Publication of the interim results of REDUCER-I is another meaningful step as we build the evidence necessary to establish the Reducer as standard of care for patients suffering from refractory angina, stated Fred Colen, President & Chief Executive Officer of Neovasc. We are encouraged by the peer-reviewed clinical data that continues to mount supporting Reducer therapy as a viable treatment option for patients that are suffering from angina-related chest pain. Its gratifying to see so many patients be able to return to the daily living activities that they have previously avoided.

 

About Reducer

The Reducer is CE-marked in the European Union and Under Investigation in the United States for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and can be completed in approximately 20 minutes.

While the Reducer is not approved for commercial use in the United States, the FDA granted Breakthrough Device designation to the Reducer in October 2018.

Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.

 

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer(TM), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara(TM), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel, and Europe. For more information, visit: www.neovasc.com.

 

Investors

Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com

 

Media

SeanLeous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com

 

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the interpretations and implications of the REDUCER-I study, the efficacy of the Reducer as a therapy for patients who suffer from refractory angina, the procedural safety and success of the Reducer, the ORBITA-COSMIC study and COSIRA-II trials helpfulness to validating the Reducer, the building of evidence necessary to establish the Reducer as standard of care for patients suffering from refractory angina, the mounting supporting of Reducer therapy as a viable treatment option for patients that are suffering from angina-related chest pain and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company’s ability to continue as a going concern; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company’s operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company’s expected schedule; risks relating to the Company’s need for significant additional future capital and the Company’s ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company’s common shares (the “Common Shares”) may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s conclusion that it did have effective internal control over financial reporting as of December 31, 2020 but not at December 31, 2019 and 2018; risks relating to the Common Share price being volatile; risks relating to the possibility that the Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s significant indebtedness, and its effect on the Company’s financial condition; risks relating to lawsuits that the Company is subject to, which could divert the Company’s resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company’s ability to establish, maintain and defend intellectual property rights in the Company’s products; risks relating to results from clinical trials of the Company’s products, which may be unfavorable or perceived as unfavorable; the Company’s history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company’s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company’s ability to achieve or maintain expected levels of market acceptance for the Company’s products, as well as the Company’s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company’s ability to convince public payors and hospitals to include the Company’s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company’s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company’s products; risks relating to health and safety concerns associated with the Company’s products and industry; risks relating to the Company’s manufacturing operations, including the regulation of the Company’s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company’s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company’s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company’s dependence on limited products for substantially all of the Company’s current revenues; risks relating to the Company’s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a “passive foreign investment company”; risks relating to breaches of anti-bribery laws by the Company’s employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company’s dependence upon key personnel to achieve its business objectives; risks relating to the Company’s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company’s management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company’s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers; and risks relating to anti-takeover provisions in the Company’s constating documents which could discourage a third-party from making a takeover bid beneficial to the Company’s shareholders. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Information Form and in the Management’s Discussion and Analysis for the three and six months ended June 30, 2021 (copies of which may be obtained atwww.sedar.comorwww.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.

Michael Burrys Tweet and Delete

Posted on by Admin

Michael Burry is Tweeting About the Markets and His Subpoena

 

About three times a year, I click to re-follow Dr. Michael Burry’s Twitter account. This is because he deletes his account about three times a year after tweeting something that I suspect he regrets. Recently the hedge fund manager that shorted the mortgage market before the financial crisis of 2008 has been tweeting and deleting up a storm. The topics are GameStop (GME), and general market and economic perceptions.

Market Tweets

In a recent flurry of tweets, he wrote the current market boom reminds him of the dot-com bubble. He compared the options-trading frenzy to the rampant speculation that helped cause the Great Depression. These tweets have since been deleted, presumably by Burry.

Burry also repeated his expectations related to index investing that he first presented openly two years ago. That is, index funds are in a bubble of sorts as demand for weak companies is increased by the larger and stronger components, meanwhile, there is little fundamental analysis to investing in indexes as opposed to individual stocks.

Burry tweeted a link to a research paper dated June of 2021 about inelastic markets. The research demonstrated that the US stock market’s value rose by $5 for every $1 invested in it. The famous hedge fund manager that runs Scion Asset Management noted the majority of millennials use passive vehicles such as index funds to buy stocks. This could further stretch prices without proper evaluation. Burry wrote, “That 5:1 ratio will get much, much sillier in time,” adding that the imbalance is a “product of a paradigm.”

Again, related to the overall market, the hedge fund manager compared the bull market during the 15 years that lead to 2000 to the growth in valuations in stocks over the past 15 years. He highlighted a 94% correlation between the Nasdaq 100’s performance in each of those periods and a 95% correlation for the S&P 500 index.

Michael Burry warned that the US stock market is risky and accused the Federal Reserve of misleading investors.  He said he was not investing in America’s largest technology companies.

The Scion founder and investment officer drew a parallel between the surge in people trading options on meme stocks and the widespread speculation that preceded the Wall Street Crash of 1929. He showed parallels to an article about the options mania with a quote by a statistician named Leroy Peavey in November 1929. Peavey blamed the market crash that year on a wave of leveraged speculation that pulled in “elevator boys, typewriter girls, and even schoolchildren.”

 

GameStop Tweet

While best known for his market shorts and portrayal in the book/movie The Big
Short,  he also was instrumental in bringing to light the potential of the GameStop short squeeze, which set off trading activity that caught many professionals off-guard. Related to recent events related to his investigations surrounding meme stock trading, Burry wrote, “So, who got an SEC subpoena over $GME? Actually, I know who, they’re on my subpoena. With all that’s going on in the world…” Burry tweeted in a now-deleted post on Friday. He attached a copy of the SEC letter dated Sept. 21. 

The hedge fund manager had been trading GameStop shares and publicly commenting on the meme stock for the past few years. At the end of 2018, Burry first revealed a $6.8 million position in the video game retailer. In 2019 he told Barron’s that new consoles from Microsoft and Sony would “extend GameStop’s life significantly,” which fueled a rally in the shares. However, when the massive GameStop short squeeze shocked Wall Street in January, Burry turned into a vocal critic of the stock, saying the trading in GameStop is “unnatural, insane, and dangerous” and there should be “legal and regulatory repercussions.”

 

Take-Away

Burry has been sounding alarm bells over Twitter and in interviews with Bloomberg for a couple of years. He’s warned of overvalued stocks dragged up by investors investing in market indexes rather than individually selecting stocks, he’s highlighted unsustainable levels of speculation in meme stocks, cryptocurrencies, and other assets and suggested it could lead to the “mother of all crashes.”

 

Paul
Hoffman

Managing Editor, Channelchek

 

Suggested Reading:



Michael Burry vs Cathie Wood is Not an Even Competition

Is the Index Bubble Michael Burry Warned About Still Looming?





Should Investors Listen to Influencers?

You Can Own a Piece of r/wallstreetbets

 

 

Sources:

https://twitter.com/MichaelJBurryMD

https://www.barrons.com/articles/big-short-investor-michal-burry-is-now-long-gamestop-51566424832

https://markets.businessinsider.com/news/stocks/big-short-michael-burry-warns-stocks-options-dotcom-bubble-crash-2021-9#:~:text=Michael%20Burry%20said%20the%20current,Invest%20as%20of%20June%2030.

https://www.nber.org/papers/w28967

https://www.cnbc.com/2021/01/27/hedge-fund-targeted-by-reddit-board-melvin-capital-closed-out-of-gamestop-short-position-tuesday.html

 

Stay up to date. Follow us:

 

Aurania Intersects Silver-Zinc Mineralization in Hole 3 at Tiria-Shimpia

Posted on by Admin


Aurania Intersects Silver-Zinc Mineralization in Hole 3 at Tiria-Shimpia

 

Toronto, Ontario, September 27, 2021 – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”) reports that the third hole drilled on the 22 kilometre-long Tiria-Shimpia silver-zinc target, intersected the extension of the mineralized layer that was seen at surface.  Hole SH-003 intersected 5 metres (“m”) at a grade of 10.5 grams per tonne (“g/t”) silver and 2.5% zinc within a 31.5m thick halo of mineralization in layered sedimentary rock in the central part of the Company’s Lost Cities – Cutucu Project area (“Project”) in southeastern Ecuador.

Aurania’s Chairman & CEO, Dr. Keith Barron commented, “We’ve finally hit significant mineralization in drill hole 3 at our Tiria-Shimpia target in the Lost Cities Project.  We have intersected the extension of mineralization exposed at surface as planned, and now we need to home in on the higher-grade parts of the system within the 22km long trend defined by metal enrichment in soil.”   

 

Details of the Mineralization Intersected in Hole SH-003

Drill hole 3 at Tiria-Shimpia was planned to intersect a layer of fracture-controlled mineralization that geological mapping at surface showed to be 20m wide and over 800m long – layer “P” in the Press Release dated April 12, 2021.  The top of the targeted layer of crackle-brecciated limestone was intersected at a depth of 35m down-hole, and mineralization occurs over 29m at a grade of 3.5g/t silver and 0.6% zinc, that contains the higher-grade interval of 5m at 10.5g/t silver and 2.5% zinc.

The crackle-brecciated limestone is sandwiched between layers of sandstone.  Pathfinder elements such as naturally-occurring arsenic, cadmium, mercury and strontium are closely related with the silver-zinc.  The whole limestone-sandstone sequence in which the mineralization occurs, shows illite clay alteration.

The sandstone is likely to have provided the permeable layers along which the mineralizing fluids flowed – providing the access required for the fluids to react with the limestone and deposit the metals.  The presence of the alteration mineral illite, indicates that the mineral-bearing fluids had a temperature of 200° to 300°C.

Hole 3 was drilled approximately 2km to the north of where holes SH-001 and SH-002 were drilled (Figure 1).  A total of 1,018 metres has been drilled in the three holes completed at Tiria-Shimpia.

The field team undertaking the silver-zinc exploration is comparing geological information observed in the drill core with their mapping at surface to determine the geometry of the system.  Soil geochemistry and MobileMT data are being incorporated into this focus on refining the target for higher-grade mineralization.  Additional drill sites will be selected from this on-going work.

Update on Scout Drilling at Tsenken N1

Drilling at hole 7 (TSN1-007) at the Company’s Tsenken N1 sediment-hosted copper-silver target has been completed and results are awaited.  Drilling at hole 8 has been started.

Figure 1.  Map of the north-central part of Tiria-Shimpia showing zinc grades in outcrop relative to silver in soil, and the positions of drill holes SH-001 to SH-003.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”)

Laboratories: The samples were prepared for analysis at MS Analytical (“MSA”) in Cuenca, Ecuador, and the analyses were done in Vancouver, Canada.

Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram sub-sample was taken.  The sub-sample was crushed to a grain size of 0.075mm and a 200 gram (“g”) split was set aside for analysis.

Analytical procedure:  Approximately 0.25g of rock pulp underwent four-acid digestion and analysis for 48 elements by ICP-MS.  For the over-limit samples, those that had a grade of greater than 1% copper, zinc and lead, and 100g/t silver, 0.4 grams of pulp underwent digestion in four acids and the resulting liquid was diluted and analyzed by ICP-MS.

QAQC: Aurania personnel inserted a certified standard pulp sample, alternating with a field blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported on above, lie within acceptable limits.  In addition, the labs reported that the analyses had passed their internal QAQC tests.

Qualified Person

The geological information contained in this news release has been verified and approved by Jean-Paul Pallier, MSc.  Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

 Dr. Richard Spencer

President

Aurania Resources Ltd.

(416) 367-3200

richard.spencer@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

QuickChek – September 27, 2021

Posted on by Admin



Kratos Receives $13.2 Million in C5ISR System Product Awards

Kratos announced that its Command, Control, Communication, Computing, Combat System, Intelligence, Surveillance and Reconnaissance (C5ISR) Business recently received approximately $13.2 million in program awards

Research, News & Market Data on Kratos



Aurania Intersects Silver-Zinc Mineralization in Hole 3 at Tiria-Shimpia

Aurania Resources announced that the third hole drilled on the 22 kilometre-long Tiria-Shimpia silver-zinc target, intersected the extension of the mineralized layer that was seen at surface

Research, News & Market Data on Aurania Resources

Watch recent presentation from Aurania Resources



Gevo Awarded Patent for Process to Upgrade or Convert Ethanol and Bio-based Alcohols to Drop-In Hydrocarbon Fuels

Gevo announced that it has received a US patent for a process that encompasses upgrading ethanol and bio-based alcohols into drop-in, bio-based diesel and jet-fuel products

Research, News & Market Data on Gevo

Watch recent presentation from Gevo



Palladium One To Host Town Hall Meeting September 28, 2021

Palladium One Mining announced that it will host a Town Hall Meeting on Tuesday, September 28 at 11:00 am EST

Research, News & Market Data on Palladium One

Watch recent presentation from Palladium One

 

Stay up to date. Follow us:

 

Gevo Awarded Patent for Process to Upgrade or Convert Ethanol and Bio-based Alcohols to Drop-In Hydrocarbon Fuels

Posted on by Admin


Gevo Awarded Patent for Process to Upgrade or Convert Ethanol and Bio-based Alcohols to Drop-In Hydrocarbon Fuels

 

ENGLEWOOD, Colo., Sept. 27, 2021 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO), announced that it has received a patent from the United States Patent and Trademark Office (“USPTO”) for a process that encompasses upgrading ethanol and bio-based alcohols into drop-in, bio-based diesel and jet-fuel products.

The USPTO has awarded Gevo U.S. Patent No. 11,078,433 titled “Conversion of Mixtures of C 2 -C 8 Olefins to Jet Fuel and/or Diesel Fuel in High Yield from Bio-Based Alcohols.” The patented process establishes a new technology and route to hydrocarbons that did not previously exist. This creates an opportunity for Gevo to diversify ethanol production to help meet increasing demand for renewable diesel and jet fuel.


Securing the patent falls in line with Gevo’s business model to develop, apply, and scale technology that can be used to produce drop-in hydrocarbon fuels. These fuels, when coupled with Gevo’s integrated-systems approach that includes regenerative agriculture and non-fossil-based renewable energy, could produce net-zero greenhouse gas (GHG) emissions over the lifecycle of the product.

“We have been working on the conversion of alcohols into hydrocarbons for many years. Ethanol, when produced using renewable energy in combination with other sustainable practices, could be a good feedstock. The technology in this patent is different from what others have done in that it provides high yields of quality diesel fuel, and can also produce SAF if we want,” says Dr. Patrick Gruber, Chief Executive Officer of Gevo. “We are believers in the ‘net-zero’ approach. We need to account for carbon and related emissions across the whole of the business system. We must pay attention to the source of renewable carbon and the energy involved with manufacturing fuel products. But that alone isn’t enough. We also have to pay attention to additional key sustainability attributes in the business system, like agricultural practices, land use, protein production, water, and all the rest. From our work on Net-Zero 1, we have a deep conviction that net-zero hydrocarbons are possible and commercially viable. We need to work to further decarbonize ethanol.”

“This patent covers technology that has the flexibility to make quality renewable diesel fuel or jet fuel from ethanol in a simple catalytic process. Producing renewable diesel makes sense in some regions of the world, whereas in others, producing high levels of jet fuel might be the right economic answer. There is a lot of overlap in the production technology used for the conversion of ethanol or isobutanol to hydrocarbons, so it shouldn’t surprise anyone that we would broaden our scope,” commented Dr. Paul Bloom, Chief Carbon and Innovation Officer of Gevo. “The combination of using decarbonized, plant-based alcohols, with our proprietary innovations to processing techniques known in the chemical industry can be a very powerful approach to dial-in the desired renewable hydrocarbon fuel product mix.

Gevo believes the grant of this patent adds additional value to the company’s intellectual property portfolio, which has previously been valued at greater than $400 million by Peak Value IP LLC in 2020.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, Gevo’s patent awards, Gevo’s patent portfolio, Gevo’s technology, Gevo’s products, the value of Gevo’s patents, Gevo’s ability to produce products with a “net-zero” greenhouse gas footprint, Gevo’s plans and strategy, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Investor and Media Contact

+1 720-647-9605

IR@gevo.com

Release – Gevo Awarded Patent for Process to Upgrade or Convert Ethanol and Bio-based Alcohols to Drop-In Hydrocarbon Fuels

Posted on by Admin


Gevo Awarded Patent for Process to Upgrade or Convert Ethanol and Bio-based Alcohols to Drop-In Hydrocarbon Fuels

 

ENGLEWOOD, Colo., Sept. 27, 2021 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO), announced that it has received a patent from the United States Patent and Trademark Office (“USPTO”) for a process that encompasses upgrading ethanol and bio-based alcohols into drop-in, bio-based diesel and jet-fuel products.

The USPTO has awarded Gevo U.S. Patent No. 11,078,433 titled “Conversion of Mixtures of C 2 -C 8 Olefins to Jet Fuel and/or Diesel Fuel in High Yield from Bio-Based Alcohols.” The patented process establishes a new technology and route to hydrocarbons that did not previously exist. This creates an opportunity for Gevo to diversify ethanol production to help meet increasing demand for renewable diesel and jet fuel.


Securing the patent falls in line with Gevo’s business model to develop, apply, and scale technology that can be used to produce drop-in hydrocarbon fuels. These fuels, when coupled with Gevo’s integrated-systems approach that includes regenerative agriculture and non-fossil-based renewable energy, could produce net-zero greenhouse gas (GHG) emissions over the lifecycle of the product.

“We have been working on the conversion of alcohols into hydrocarbons for many years. Ethanol, when produced using renewable energy in combination with other sustainable practices, could be a good feedstock. The technology in this patent is different from what others have done in that it provides high yields of quality diesel fuel, and can also produce SAF if we want,” says Dr. Patrick Gruber, Chief Executive Officer of Gevo. “We are believers in the ‘net-zero’ approach. We need to account for carbon and related emissions across the whole of the business system. We must pay attention to the source of renewable carbon and the energy involved with manufacturing fuel products. But that alone isn’t enough. We also have to pay attention to additional key sustainability attributes in the business system, like agricultural practices, land use, protein production, water, and all the rest. From our work on Net-Zero 1, we have a deep conviction that net-zero hydrocarbons are possible and commercially viable. We need to work to further decarbonize ethanol.”

“This patent covers technology that has the flexibility to make quality renewable diesel fuel or jet fuel from ethanol in a simple catalytic process. Producing renewable diesel makes sense in some regions of the world, whereas in others, producing high levels of jet fuel might be the right economic answer. There is a lot of overlap in the production technology used for the conversion of ethanol or isobutanol to hydrocarbons, so it shouldn’t surprise anyone that we would broaden our scope,” commented Dr. Paul Bloom, Chief Carbon and Innovation Officer of Gevo. “The combination of using decarbonized, plant-based alcohols, with our proprietary innovations to processing techniques known in the chemical industry can be a very powerful approach to dial-in the desired renewable hydrocarbon fuel product mix.

Gevo believes the grant of this patent adds additional value to the company’s intellectual property portfolio, which has previously been valued at greater than $400 million by Peak Value IP LLC in 2020.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, Gevo’s patent awards, Gevo’s patent portfolio, Gevo’s technology, Gevo’s products, the value of Gevo’s patents, Gevo’s ability to produce products with a “net-zero” greenhouse gas footprint, Gevo’s plans and strategy, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Investor and Media Contact

+1 720-647-9605

IR@gevo.com

Michael Burry’s Tweet and Delete

Posted on by Admin

Michael Burry is Tweeting About the Markets and His Subpoena

 

About three times a year, I click to re-follow Dr. Michael Burry’s Twitter account. This is because he deletes his account about three times a year after tweeting something that I suspect he regrets. Recently the hedge fund manager that shorted the mortgage market before the financial crisis of 2008 has been tweeting and deleting up a storm. The topics are GameStop (GME), and general market and economic perceptions.

Market Tweets

In a recent flurry of tweets, he wrote the current market boom reminds him of the dot-com bubble. He compared the options-trading frenzy to the rampant speculation that helped cause the Great Depression. These tweets have since been deleted, presumably by Burry.

Burry also repeated his expectations related to index investing that he first presented openly two years ago. That is, index funds are in a bubble of sorts as demand for weak companies is increased by the larger and stronger components, meanwhile, there is little fundamental analysis to investing in indexes as opposed to individual stocks.

Burry tweeted a link to a research paper dated June of 2021 about inelastic markets. The research demonstrated that the US stock market’s value rose by $5 for every $1 invested in it. The famous hedge fund manager that runs Scion Asset Management noted the majority of millennials use passive vehicles such as index funds to buy stocks. This could further stretch prices without proper evaluation. Burry wrote, “That 5:1 ratio will get much, much sillier in time,” adding that the imbalance is a “product of a paradigm.”

Again, related to the overall market, the hedge fund manager compared the bull market during the 15 years that lead to 2000 to the growth in valuations in stocks over the past 15 years. He highlighted a 94% correlation between the Nasdaq 100’s performance in each of those periods and a 95% correlation for the S&P 500 index.

Michael Burry warned that the US stock market is risky and accused the Federal Reserve of misleading investors.  He said he was not investing in America’s largest technology companies.

The Scion founder and investment officer drew a parallel between the surge in people trading options on meme stocks and the widespread speculation that preceded the Wall Street Crash of 1929. He showed parallels to an article about the options mania with a quote by a statistician named Leroy Peavey in November 1929. Peavey blamed the market crash that year on a wave of leveraged speculation that pulled in “elevator boys, typewriter girls, and even schoolchildren.”

 

GameStop Tweet

While best known for his market shorts and portrayal in the book/movie The Big
Short,  he also was instrumental in bringing to light the potential of the GameStop short squeeze, which set off trading activity that caught many professionals off-guard. Related to recent events related to his investigations surrounding meme stock trading, Burry wrote, “So, who got an SEC subpoena over $GME? Actually, I know who, they’re on my subpoena. With all that’s going on in the world…” Burry tweeted in a now-deleted post on Friday. He attached a copy of the SEC letter dated Sept. 21. 

The hedge fund manager had been trading GameStop shares and publicly commenting on the meme stock for the past few years. At the end of 2018, Burry first revealed a $6.8 million position in the video game retailer. In 2019 he told Barron’s that new consoles from Microsoft and Sony would “extend GameStop’s life significantly,” which fueled a rally in the shares. However, when the massive GameStop short squeeze shocked Wall Street in January, Burry turned into a vocal critic of the stock, saying the trading in GameStop is “unnatural, insane, and dangerous” and there should be “legal and regulatory repercussions.”

 

Take-Away

Burry has been sounding alarm bells over Twitter and in interviews with Bloomberg for a couple of years. He’s warned of overvalued stocks dragged up by investors investing in market indexes rather than individually selecting stocks, he’s highlighted unsustainable levels of speculation in meme stocks, cryptocurrencies, and other assets and suggested it could lead to the “mother of all crashes.”

 

Paul
Hoffman

Managing Editor, Channelchek

 

Suggested Reading:



Michael Burry vs Cathie Wood is Not an Even Competition

Is the Index Bubble Michael Burry Warned About Still Looming?





Should Investors Listen to Influencers?

You Can Own a Piece of r/wallstreetbets

 

 

Sources:

https://twitter.com/MichaelJBurryMD

https://www.barrons.com/articles/big-short-investor-michal-burry-is-now-long-gamestop-51566424832

https://markets.businessinsider.com/news/stocks/big-short-michael-burry-warns-stocks-options-dotcom-bubble-crash-2021-9#:~:text=Michael%20Burry%20said%20the%20current,Invest%20as%20of%20June%2030.

https://www.nber.org/papers/w28967

https://www.cnbc.com/2021/01/27/hedge-fund-targeted-by-reddit-board-melvin-capital-closed-out-of-gamestop-short-position-tuesday.html

 

Stay up to date. Follow us: